412 related articles for article (PubMed ID: 34391789)
1. PARkinson's: From cellular mechanisms to potential therapeutics.
Lengyel-Zhand Z; Puentes LN; Mach RH
Pharmacol Ther; 2022 Feb; 230():107968. PubMed ID: 34391789
[TBL] [Abstract][Full Text] [Related]
2. Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases.
Park H; Kam TI; Dawson TM; Dawson VL
Int Rev Cell Mol Biol; 2020; 353():1-29. PubMed ID: 32381174
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease.
Kam TI; Mao X; Park H; Chou SC; Karuppagounder SS; Umanah GE; Yun SP; Brahmachari S; Panicker N; Chen R; Andrabi SA; Qi C; Poirier GG; Pletnikova O; Troncoso JC; Bekris LM; Leverenz JB; Pantelyat A; Ko HS; Rosenthal LS; Dawson TM; Dawson VL
Science; 2018 Nov; 362(6414):. PubMed ID: 30385548
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) in the pathogenesis of Parkinson's disease.
Lee Y; Kang HC; Lee BD; Lee YI; Kim YP; Shin JH
BMB Rep; 2014 Aug; 47(8):424-32. PubMed ID: 24874851
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors and Parkinson's Disease.
Olsen AL; Feany MB
N Engl J Med; 2019 Jan; 380(5):492-494. PubMed ID: 30699325
[No Abstract] [Full Text] [Related]
7. Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities.
Xu X; Sun B; Zhao C
Neurobiol Dis; 2023 Oct; 187():106314. PubMed ID: 37783233
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
9. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
[TBL] [Abstract][Full Text] [Related]
10. Arsenite-induced cytotoxicity is regulated by poly-ADP ribose polymerase 1 activation and parthanatos in p53-deficient H1299 cells: The roles of autophagy and p53.
So KY; Oh SH
Biochem Biophys Res Commun; 2023 May; 656():78-85. PubMed ID: 36958258
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
12. Genetic and pharmacological PARP inhibition reduces axonal degeneration in C. elegans models of ALS.
Tossing G; Livernoche R; Maios C; Bretonneau C; Labarre A; Parker JA
Hum Mol Genet; 2022 Sep; 31(19):3313-3324. PubMed ID: 35594544
[TBL] [Abstract][Full Text] [Related]
13. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
14. Mediation of cell death by poly(ADP-ribose) polymerase-1.
Koh DW; Dawson TM; Dawson VL
Pharmacol Res; 2005 Jul; 52(1):5-14. PubMed ID: 15911329
[TBL] [Abstract][Full Text] [Related]
15. Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei.
Schlesinger M; Vilchez Larrea SC; Haikarainen T; Narwal M; Venkannagari H; Flawiá MM; Lehtiö L; Fernández Villamil SH
Parasit Vectors; 2016 Mar; 9():173. PubMed ID: 27007296
[TBL] [Abstract][Full Text] [Related]
16. New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
Liu C; Fang Y
Biochem Pharmacol; 2019 Sep; 167():58-63. PubMed ID: 31034795
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose)--a unique natural polymer structural features, biological role and approaches to the chemical synthesis.
Drenichev MS; Mikhailov SN
Nucleosides Nucleotides Nucleic Acids; 2015; 34(4):258-76. PubMed ID: 25774719
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
19. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.
Fatokun AA; Dawson VL; Dawson TM
Br J Pharmacol; 2014 Apr; 171(8):2000-16. PubMed ID: 24684389
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) signaling in cell death.
Virág L; Robaszkiewicz A; Rodriguez-Vargas JM; Oliver FJ
Mol Aspects Med; 2013 Dec; 34(6):1153-67. PubMed ID: 23416893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
